Immunotherapy-Induced Endocrinopathies And Their Management In Cancer Patients A Prospective Observational Study

Abstract

Background: Immunotherapy has been transformational in cancer care, but here is the catch; it can lead to endocrine disorders that affect hormone balance and patient health.

Methodology: this study investigated the incidence, management, and outcomes of endocrinopathies amongst the cancer patients undergoing immunotherapy.

Study design: A Prospective observational study.

Place & Duration of Study: Department of endocrolong hmc Peshawar from jan 2019 to dec 2019

Methods:

The current study monitored twice as many individuals (n=200) under immunotherapy due to immune-related adverse events (irAEs) which affected their endocrine functions. Diagnosis and management of conditions such as thyroiditis, hypophysitis, adrenalitis, and diabetes mellitus were conducted using biochemical tests which included hormone levels, and imaging techniques including MRI or CT scans. Patients were provided with individualized treatments by a team consisting of multiple specialists.

Results:

Among the 200 participants, 45 (22.5%) developed an endocrinopathy most of which were thyroiditis. With this technique, a total of 88.9% of patients regained their illness status and continued with cancer chemotherapy regimens. This measure improved standard of living in major ways by effectively managing the associated disorders of endocrine system and as well as preserving therapy efficacy for neoplastic diseases.

Conclusion: our monitoring and interdisciplinary management, Cancer patients can maintain normal hormones through immunotherapy-induced endocrinopathies while staying on treatment protocol.